Skip to main content

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Oct 29, 2020 8:43 pm

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on is a digital platform dedicated to rheumatology.  Written by rheums for rheums we provide daily news, insights & perspectives on the field.  If you scan our daily news (email), 15 seconds and you’ll know what's up in rheumatology. We only provide the stuff we deem to be important and encourage you to create and join the conversation by signing in and commenting, vote on our surveys, follow us on social media or enjoying our videos and podcasts.  Please let me know when you have a suggestion, gripe, new idea or novel case – by using our “back talk” – find the tab on our email and website.

Look for these ACR2020 Virtual Bonus Features as RheumNow covers our annual meeting starting next week:

  • ACR IQ 
  • ACR Topic Chat
  • ACR Virtual Playbook
  • Pre meeting and Post meeting coverage
  • "ACR Best" tweets
  • Top 5 of the day lists
  • Perspective videos 
  • Midmeeting Recap Saturday night
  • Rheumatology Roundup Monday night
  1. Metaanalysis of 7 cohort studies, 34 029 biologic & 135370 biologic-naive Pts (RA, PsO, IBD) looked at risk of melanoma (vs conventional Rx). Found no statistically significant increase risk for melanoma w/ biologics (eg RA RR 1.2; 95% CI, 0.83-1.74)
  2. International psoriasis registry reports Less hospitalization in PSO on biologics (16% vs 33%); higher HR 2.8 on non-biologics. 374 Psoriasis pts w/ COVID-19, 71% on biologic, 18% non-biologic & 10% no systemic Rx. 93% fully recovered. 21% hospitalized, 2% died.
  3. 25 pts w/ refractory Juvenile dermatomyositis (JDM) were treated w/ JAK inhib (tofacitinib, ruxolitinib) - all showed improved rashes, including 66.7% with complete resolution; 40% had decreased muscle strength; 28% discontinued glucocorticoids
  4. Population study from NY of 168,234 hip replacements and 308,477 knee TKAs showed that total joint arthroplasty was associated with a 34-44% decrease risk of falls (THA HR 0.56; TKA HR 0.66). Risk of falls incr w/ age- 70-79 yrs (HR4.3), 80+ yrs (HR 5.5)
  5. Autoantibodies can be found in COVID-19 pts (including ANA, RF, -RNP centromere and antibobides against phospholipids (3/52), prothrombin (2/52), and c-ANCA (2/52)) (THIS IS A PREPRINT)
  6. Review of 127 pts w/ diagnostic criteria for palindromic rheumatism - Most affected JTS were wrist, knee, MCP; 34% later developed CTD (28% RA, 2% lupus 3% other CTD). Progression predicted by +RF (HR 2.9), PIP (HR 2.4), Wrist (HR 2.5) & female (HR 2.2)
  7. Safety of nintedinib (NIN) in PSS-ILD - 576 PSS pts given NIN 150 mg bid or PBO x52wks. Dose lowered to 100 mg bid for AE. Diarrhea seen in 76% of NIN and 32% in PBO (d/c in 6.9% & 0.3%). Dose reduction in 48% & 12%. RCT discontinuation in 16% & 8.7%
  8. PI facts: did you know that JAK inhibitors (UPA, Bari, Tofa) have a warning against use w/ severe liver problems. They have not been studied in pts w/ Hepatitis B or C. UPA Bari & toga can be used in mild liver dz; Tofa only at 5 mg/d w/ moderate liver dz
  9. Abatacept in Early Systemic Sclerosis    
  10. Immune Necrotizing Myopathy  
  11. Telemedicine Outcomes in RA Care 
The author has received compensation as an advisor or consultant on this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.